二甲双胍使用可逆转结核病治疗期间糖尿病相关死亡率升高
这项回顾性队列研究纳入2416例年龄≥13岁、接受培养确诊药物敏感肺结核治疗的患者,评估糖尿病对治疗期间死亡和2个月痰培养转阴的影响,以及二甲双胍对生存的影响。调整多种混杂因素后,糖尿病患者治疗期间死亡 odds 为无糖尿病者的1.91倍(95%CI 1.51-2.40),2个月仍培养阳性 odds 为1.72倍(95%CI 1.25-2.38);糖尿病患者使用二甲双胍与治疗期间死亡率降低显著相关(HR 0.56,95%CI 0.39-0.82),使用者死亡率与无糖尿病者相似。作者认为二甲双胍可能作为辅助性宿主导向治疗。
要点
- 糖尿病患者结核治疗期间死亡 odds 为无糖尿病者1.91倍(95%CI 1.51-2.40)。
- 糖尿病患者2个月痰培养仍阳性 odds 为无糖尿病者1.72倍(95%CI 1.25-2.38)。
- 糖尿病患者使用二甲双胍与治疗期间死亡率降低相关(HR 0.56,95%CI 0.39-0.82)。
核心结论
- 本研究提示,尽管存在多种潜在混杂变量,糖尿病仍与结核治疗不良结局风险增加相关。
- 二甲双胍使用与结核治疗期间死亡率降低显著相关,提示该药可能作为辅助性宿主导向治疗。
研究设计与样本
- 回顾性队列研究,纳入2416例年龄≥13岁、接受培养确诊药物敏感肺结核治疗的患者。
主要发现
- 调整年龄、性别、慢性肾病、癌症、丙型肝炎、吸烟、空洞性疾病和治疗依从性后,糖尿病患者结核治疗期间死亡 odds 为无糖尿病者的1.91倍(95%CI 1.51-2.40)。
- 糖尿病患者2个月时仍培养阳性的 odds 为无糖尿病者的1.72倍(95%CI 1.25-2.38)。
- 糖尿病患者使用二甲双胍与结核治疗期间死亡率降低显著相关(HR 0.56,95%CI 0.39-0.82)。
- 二甲双胍使用者死亡率与无糖尿病患者相似。
临床怎么用
- 作者认为二甲双胍可能作为辅助性宿主导向治疗,原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global type 2 diabetes mellitus (DM) epidemic threatens progress made in reducing tuberculosis (TB)-related mortality worldwide. Previous clinical studies have not fully evaluated potential confounding variables in addressing the impact of DM on TB treatment outcomes. The antidiabetic agent metformin regulates autophagy and may play a role as a host-directed therapeutic adjuvant to antitubercular treatment. METHODS: We conducted a retrospective cohort study comprising patients aged ≥13 years undergoing treatment for culture-confirmed, drug-susceptible pulmonary TB. We assessed the effect of DM on mortality during TB treatment and 2-month TB sputum-culture conversion. We also evaluated the effect of metformin use on survival during TB treatment. RESULTS: Among 2416 patients undergoing TB treatment, after adjusting for age, sex, chronic kidney disease, cancer, hepatitis C, tobacco use, cavitary disease, and treatment adherence, patients with DM had 1.91 times higher odds (95% confidence interval [CI], 1.51-2.40) of death during TB treatment than patients without DM, and 1.72 (95% CI, 1.25-2.38) times higher odds of remaining culture-positive at 2 months. Metformin use in patients with DM was significantly associated with decreased mortality during TB treatment (hazard ratio, 0.56 [95% CI, .39-.82]), and metformin users had similar mortality as patients without DM. CONCLUSIONS: This study suggests that despite multiple potential confounding variables, DM poses an increased risk of adverse TB treatment outcomes. There was a significant association between metformin use and decreased mortality during TB treatment, suggesting a potential role for this agent as adjunctive, host-directed therapy.
引用
- Degner NR, Wang JY, Golub JE, et al. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis. 2018. PMID: 29325084. doi:10.1093/cid/cix819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。